MCID: INT066
MIFTS: 63

Interstitial Lung Disease

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Interstitial Lung Disease

MalaCards integrated aliases for Interstitial Lung Disease:

Name: Interstitial Lung Disease 12 72 49 14
Lung Diseases, Interstitial 41 69
Lung Diseases Interstitial 51
Interstitial Lung Diseases 40
Ild 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3082
ICD10 32 J84.9
MeSH 41 D017563
SNOMED-CT 64 233703007 64667001
UMLS 69 C0206062

Summaries for Interstitial Lung Disease

NIH Rare Diseases : 49 Interstitial lung diseases (ILDs) are a large group of disorders characterized by thickening of the walls between the alveoli, increased production and buildup of collagen, and pulmonary fibrosis (progressive scarring of lung tissue). The scarring eventually affects the ability to breathe and get enough oxygen into the bloodstream. Symptoms typically include shortness of breath and a dry cough. There are numerous possible causes of ILD, including connective tissue disorders, autoimmune diseases (e.g. rheumatoid arthritis), occupational exposures (such as asbestos), infection, and many drugs. Specific diseases leading to ILD may include sarcoidosis, pulmonary Langerhans cell histiocytosis, and eosinophilic pulmonary diseases. The list of substances and conditions that can lead to ILD is long. However, in many cases, the cause is not known. Some cases of unknown cause that share similar characteristics are called idiopathic interstitial pneumonias. Lung scarring that occurs in ILD is permanent. However, some treatments may temporarily improve symptoms or slow the disease's progress. Treatment options may include various medications, oxygen therapy, pulmonary rehabilitation, and as a last resort, lung transplantation. Last updated: 7/31/2017

MalaCards based summary : Interstitial Lung Disease, also known as lung diseases, interstitial, is related to desquamative interstitial pneumonia and surfactant dysfunction, and has symptoms including snoring, hemoptysis and coughing. An important gene associated with Interstitial Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are ERK Signaling and Metabolism of proteins. The drugs Bosentan and Iloprost have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

MedlinePlus : 40 Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. The inflammation and scarring make it hard to get enough oxygen. The scarring is called pulmonary fibrosis. Breathing in dust or other particles in the air is responsible for some types of interstitial lung diseases. Specific types include Black lung disease among coal miners, from inhaling coal dust Farmer's lung, from inhaling farm dust Asbestosis, from inhaling asbestos fibers Siderosis, from inhaling iron from mines or welding fumes Silicosis, from inhaling silica dust Other causes include autoimmune diseases or occupational exposures to molds, gases, or fumes. Some types of interstitial lung disease have no known cause. Treatment depends on the type of exposure and the stage of the disease. It may involve medicines, oxygen therapy, or a lung transplant in severe cases.

Wikipedia : 72 Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of lung diseases... more...

Related Diseases for Interstitial Lung Disease

Diseases related to Interstitial Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 desquamative interstitial pneumonia 32.8 ABCA3 MUC5B SFTPC
2 surfactant dysfunction 32.8 ABCA3 SFTPB SFTPC
3 dermatomyositis 32.7 IFIH1 IL1A SFTPD
4 extrinsic allergic alveolitis 32.3 CCL2 CCL5 CXCL8 IL1B SFTPD
5 bagassosis 32.0 CXCL8 IL1B
6 pulmonary fibrosis 31.8 CCL2 EDN1 IL1B MUC5B SFTPC SFTPD
7 beryllium disease 31.8 TGFB1 TNF
8 connective tissue disease 31.3 IL1A MUC1 SFTPD TNF
9 pneumoconiosis 30.9 CCL2 CXCL8 IL1A IL1B MUC5B TGFB1
10 arthritis 30.8 CCL2 CXCL8 IL1A IL1B TNF
11 bronchiolitis 30.7 CCL5 CXCL8 MUC5B TNF
12 idiopathic pleuroparenchymal fibroelastosis 30.5 MUC1 SFTPD
13 esophagitis 30.5 CXCL8 IL1B TGFB1
14 rheumatoid arthritis 30.3 CCL2 CCL5 CXCL8 IL1A IL1B TGFB1
15 sleep apnea 30.2 CXCL8 EDN1 TNF
16 eosinophilic pneumonia 30.2 CCL17 CCL5 SFTPD
17 neonatal respiratory failure 30.1 ABCA3 SFTPB SFTPC
18 pulmonary alveolar proteinosis 30.1 CCL2 SFTPB SFTPC SFTPD
19 pleurisy 30.0 CCL2 CXCL8 TNF
20 systemic scleroderma 30.0 EDN1 SFTPD TGFB1
21 pulmonary sarcoidosis 29.9 CCL2 CCL5 SFTPD TNF
22 uveitis 29.7 CCL2 IL1A TNF
23 lung disease 29.7 ABCA3 CCL2 CCL5 CXCL8 EDN1 IFIH1
24 pneumonia 29.7 CCL2 CCL5 CXCL8 IL1B MUC5B SFTPB
25 idiopathic interstitial pneumonia 29.6 CCL2 CXCL8 EDN1 MUC5B SFTPC SFTPD
26 periodontitis 29.5 CCL2 CXCL8 IL1A IL1B TNF
27 acute respiratory distress syndrome 29.5 CXCL8 IL1B SFTPB SFTPC SFTPD TNF
28 respiratory failure 29.4 CXCL8 EDN1 NKX2-1 SFTPB SFTPC SFTPD
29 lung cancer susceptibility 3 29.3 EGFR MUC1 NKX2-1 SFTPB SFTPC
30 psoriasis 28.6 CCL17 CCL2 CCL5 CXCL8 IFIH1 IL1A
31 asthma 28.5 CCL17 CCL2 CCL5 CXCL8 EDN1 IL1A
32 pulmonary fibrosis, idiopathic 27.6 ABCA3 CCL17 CCL2 CCL5 CXCL8 EDN1
33 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.4
34 children's interstitial lung disease 12.4
35 respiratory bronchiolitis-interstitial lung disease syndrome 12.2
36 drug or radiation exposure-related interstitial lung disease 12.1
37 interstitial pneumonitis, desquamative, familial 11.8
38 surfactant metabolism dysfunction, pulmonary, 2 11.7
39 autoimmune interstitial lung, joint, and kidney disease 11.6
40 antisynthetase syndrome 11.4
41 sting-associated vasculopathy, infantile-onset 11.4
42 surfactant metabolism dysfunction, pulmonary, 1 11.4
43 surfactant metabolism dysfunction, pulmonary, 3 11.4
44 pulmonary alveolar microlithiasis 11.0
45 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 11.0
46 mucoepithelial dysplasia, hereditary 10.9
47 niemann-pick disease, type c2 10.9
48 interstitial lung and liver disease 10.9
49 anthracosis 10.9
50 tracheal agenesis 10.7 SFTPB SFTPD

Graphical network of the top 20 diseases related to Interstitial Lung Disease:



Diseases related to Interstitial Lung Disease

Symptoms & Phenotypes for Interstitial Lung Disease

UMLS symptoms related to Interstitial Lung Disease:


snoring, hemoptysis, coughing

GenomeRNAi Phenotypes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR TGFB1
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR TGFB1

MGI Mouse Phenotypes related to Interstitial Lung Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.18 TNF SFTPC SFTPD TF TGFB1 NKX2-1
2 homeostasis/metabolism MP:0005376 10.17 TNF SFTPD TF TGFB1 SFTPB IL1A
3 cardiovascular system MP:0005385 10.13 TNF SFTPC TGFB1 NKX2-1 IL1A ABCA3
4 hematopoietic system MP:0005397 10.11 TNF SFTPD TF TGFB1 IL1A CCL17
5 immune system MP:0005387 10.07 SFTPC SFTPD TGFB1 TNF IL1A IL1B
6 mortality/aging MP:0010768 10 SFTPB TNF SFTPC SFTPD TF TGFB1
7 neoplasm MP:0002006 9.56 SFTPC TGFB1 TNF IL1A IL1B ITGA3
8 respiratory system MP:0005388 9.32 SFTPC SFTPD TGFB1 TNF SFTPB ABCA3

Drugs & Therapeutics for Interstitial Lung Disease

Drugs for Interstitial Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2,Phase 3 147536-97-8 104865
2
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3 78919-13-8 6443959
3
Menthol Approved Phase 4 2216-51-5 16666
4
Gefitinib Approved, Investigational Phase 4,Phase 3 184475-35-2 123631
5
Pirfenidone Approved, Investigational Phase 4,Phase 2 53179-13-8 40632
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Methylprednisolone Approved, Vet_approved Phase 4,Early Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Early Phase 1 50-24-8 5755
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
11 Antihypertensive Agents Phase 4,Phase 3,Phase 2
12 Endothelin Receptor Antagonists Phase 4,Phase 2,Phase 3
13 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3
14 Phosphodiesterase Inhibitors Phase 4,Phase 3
15 Sildenafil Citrate Phase 4 171599-83-0
16 Vasodilator Agents Phase 4,Phase 2,Phase 3
17 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
19 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Early Phase 1
20 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
22 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2
26 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
27 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
28 Analgesics Phase 4,Phase 2
29 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Autonomic Agents Phase 4,Phase 1,Early Phase 1
31 Protective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
32 Analgesics, Non-Narcotic Phase 4,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
34 Anesthetics, General Phase 4,Phase 1
35 Anesthetics, Inhalation Phase 4,Phase 1
36 Analgesics, Opioid Phase 4
37 Narcotics Phase 4
38 Antiemetics Phase 4,Early Phase 1
39 Gastrointestinal Agents Phase 4,Early Phase 1
40 Methylprednisolone acetate Phase 4,Early Phase 1
41 Methylprednisolone Hemisuccinate Phase 4,Early Phase 1
42 Neuroprotective Agents Phase 4,Early Phase 1
43 Prednisolone acetate Phase 4,Early Phase 1
44 Prednisolone hemisuccinate Phase 4,Early Phase 1
45 Prednisolone phosphate Phase 4,Early Phase 1
46 Citrate Nutraceutical Phase 4
47 Calamus Nutraceutical Phase 4
48
Treprostinil Approved, Investigational Phase 3,Phase 2 81846-19-7 6918140 54786
49
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
50
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 245)

# Name Status NCT ID Phase Drugs
1 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
2 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Unknown status NCT00625079 Phase 4 sildenafil;sildenafil
3 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Unknown status NCT02286063 Phase 4 Ambulatory Oxygen
4 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Unknown status NCT00625469 Phase 4 bosentan
5 Pulmonary Rehabilitation in Interstitial Lung Diseases Completed NCT00882817 Phase 4
6 Iressa Case Control Study in Japan Completed NCT00252759 Phase 4
7 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
8 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep Recruiting NCT02150616 Phase 4 Oxygen;Sham oxygen (room air)
9 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance Recruiting NCT02143687 Phase 4 Oxygen;Sham oxygen (room air)
10 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride
11 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
12 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
13 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Unknown status NCT00705133 Phase 3 treprostinil
14 Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection Unknown status NCT00841750 Phase 3
15 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
16 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
17 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3 bosentan
18 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
19 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
20 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
21 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
22 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
23 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3 1% lignocaine;2% lignocaine
24 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
25 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
26 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
27 Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Recruiting NCT01570764 Phase 3 Cyclophosphamide;Placebo
28 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Recruiting NCT02999178 Phase 3 Nintedanib;Placebo
29 Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Recruiting NCT02896205 Phase 3 Mycophenolate mofetil;Placebo
30 Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases Recruiting NCT02990286 Phase 3 Rituximab;Placebo of Rituximab;Mycophenolate Mofetil
31 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
32 A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. Recruiting NCT03313180 Phase 3 Nintedanib
33 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Recruiting NCT02630316 Phase 2, Phase 3 Inhaled Treprostinil;Placebo
34 Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease Recruiting NCT03241420 Phase 3
35 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Active, not recruiting NCT02597933 Phase 3 Nintedanib;Placebo
36 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Active, not recruiting NCT02474355 Phase 3 AZD9291 Dosing
37 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Active, not recruiting NCT01973998 Phase 3 Roflumilast;Placebo
38 An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Enrolling by invitation NCT02633293 Phase 2, Phase 3 Inhaled Treprostinil
39 Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Not yet recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
40 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
41 Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure Terminated NCT03262571 Phase 3
42 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
43 GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Terminated NCT01257802 Phase 3 depot leuprolide acetate 3.75 mg;Placebo
44 Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease Unknown status NCT01450644 Phase 2
45 Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air Unknown status NCT01140685 Phase 2
46 Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease Completed NCT02594839 Phase 1, Phase 2 Bone marrow mesenchymal stem cells;Placebo
47 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
48 Ambulatory Oxygen for ILD Completed NCT01906931 Phase 2
49 Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Completed NCT01933334 Phase 2 Pirfenidone
50 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo

Search NIH Clinical Center for Interstitial Lung Disease

Cochrane evidence based reviews: lung diseases, interstitial

Genetic Tests for Interstitial Lung Disease

Anatomical Context for Interstitial Lung Disease

MalaCards organs/tissues related to Interstitial Lung Disease:

38
Lung, Testes, Heart, Bone, Skeletal Muscle, Skin, Monocytes

Publications for Interstitial Lung Disease

Articles related to Interstitial Lung Disease:

(show top 50) (show all 1013)
# Title Authors Year
1
Screening High Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. ( 29426066 )
2018
2
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). ( 29414453 )
2018
3
Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. ( 29452423 )
2018
4
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( 29382307 )
2018
5
Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO! ( 29415370 )
2018
6
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
7
Advocating for early interstitial lung disease detection in mixed connective tissue disease. ( 28977485 )
2018
8
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. ( 29376545 )
2018
9
Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. ( 28379478 )
2018
10
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. ( 29343236 )
2018
11
Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. ( 29417209 )
2018
12
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
13
Chronic interstitial lung disease in children. ( 29436403 )
2018
14
Clinical and pathological characteristics of IgG4-related interstitial lung disease. ( 29434730 )
2018
15
Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. ( 29413504 )
2018
16
Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. ( 29353024 )
2018
17
The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. ( 29346191 )
2018
18
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease. ( 29411180 )
2018
19
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
20
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. ( 29414297 )
2018
21
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. ( 29422324 )
2018
22
Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. ( 29446698 )
2018
23
International management platform for children's interstitial lung disease (chILD-EU). ( 29056600 )
2018
24
Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. ( 29348183 )
2018
25
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. ( 29382380 )
2018
26
Cyclophosphamide for connective tissue disease-associated interstitial lung disease. ( 29297205 )
2018
27
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
28
CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. ( 29140119 )
2018
29
Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. ( 29422289 )
2018
30
Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine. ( 28736065 )
2017
31
Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency. ( 28924106 )
2017
32
Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia. ( 28748819 )
2017
33
FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). ( 27896807 )
2017
34
Interstitial lung disease in systemic sclerosis: current and future treatment. ( 28063071 )
2017
35
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. ( 28870955 )
2017
36
Concomitant lung cancer and interstitial lung disease: A challenge in clinical practice. ( 28063797 )
2017
37
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
38
Pathologic Separation of Chronic Hypersensitivity Pneumonitis From Fibrotic Connective Tissue Disease-associated Interstitial Lung Disease. ( 28614213 )
2017
39
Human Herpesvirus 8 in Perinatally HIV-infected Children with Interstitial Lung Disease. ( 29165615 )
2017
40
Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. ( 28842784 )
2017
41
A 64-year-old woman with interstitial lung disease and positive antibodies against aminoacyl-transfer RNA synthetases in the absence of myositis: presentation of an anti-PL-12 positive antisynthetase syndrome. ( 29173135 )
2017
42
Exercise training improves exercise capacity and quality of life in people with interstitial lung disease [synopsis]. ( 28888691 )
2017
43
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. ( 28488124 )
2017
44
Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. ( 28915678 )
2017
45
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. ( 27682649 )
2017
46
Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. ( 28666014 )
2017
47
Interstitial Lung Disease Associated with Adult Niemann-Pick Disease Type B. ( 28601876 )
2017
48
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. ( 28619061 )
2017
49
Filamin A (FLNA) mutation-A newcomer to the childhood interstitial lung disease (ChILD) classification. ( 28898549 )
2017
50
Can we effectively use radiographic imaging and clinical parameters for making an earlier diagnosis of granulomatous interstitial lung disease in patients with common variable immunodeficiency? ( 28477784 )
2017

Variations for Interstitial Lung Disease

Expression for Interstitial Lung Disease

Search GEO for disease gene expression data for Interstitial Lung Disease.

Pathways for Interstitial Lung Disease

Pathways related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
2
Show member pathways
13.83 ABCA3 CCL2 CXCL8 IFIH1 MUC1 MUC5B
3
Show member pathways
13.69 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
4
Show member pathways
13.57 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
5
Show member pathways
13.39 CCL2 CCL5 CXCL8 EGFR IL1A IL1B
6
Show member pathways
13.39 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
7
Show member pathways
13.3 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
8
Show member pathways
12.96 CCL2 CCL5 CXCL8 EDN1 EGFR IL1A
9
Show member pathways
12.86 CXCL8 IL1A IL1B TGFB1 TNF
10
Show member pathways
12.81 CCL2 CCL5 CXCL8 IFIH1 IL1A IL1B
11 12.78 EGFR IL1A IL1B TGFB1 TNF
12
Show member pathways
12.75 CCL5 CXCL8 IFIH1 IL1B TNF
13
Show member pathways
12.73 EGFR IL1A IL1B TGFB1 TNF
14
Show member pathways
12.62 CCL2 EGFR IL1B ITGA3 TNF
15 12.6 CCL2 CCL5 IFIH1 IL1B TNF
16
Show member pathways
12.56 CCL2 CCL5 CXCL8 IL1B TGFB1 TNF
17
Show member pathways
12.35 CCL2 CCL5 IL1B TNF
18
Show member pathways
12.32 CCL17 CCL2 CXCL8 IL1B MUC5B TNF
19
Show member pathways
12.29 CXCL8 IL1A IL1B TNF
20
Show member pathways
12.28 IL1A IL1B TGFB1 TNF
21 12.25 IL1A IL1B TGFB1 TNF
22
Show member pathways
12.22 CCL17 CCL2 CCL5 CXCL8 ITGA3
23
Show member pathways
12.22 CXCL8 IL1B MUC1 SFTPD TNF
24 12.21 CXCL8 IL1A IL1B TF TNF
25
Show member pathways
12.19 CXCL8 IL1A IL1B TNF
26 12.11 CCL2 EDN1 IL1A IL1B TNF
27 12.08 IL1A IL1B TGFB1 TNF
28
Show member pathways
12.03 CCL17 CCL2 CCL5 CXCL8
29 11.99 CXCL8 IL1A IL1B TGFB1
30 11.99 CCL2 CXCL8 EGFR IL1A IL1B TGFB1
31 11.96 CCL2 CCL5 EDN1 IL1B TNF
32 11.94 IL1A IL1B ITGA3 TNF
33 11.93 CXCL8 IL1B TGFB1 TNF
34 11.92 CCL2 CXCL8 IL1A IL1B MUC1 TGFB1
35 11.83 CXCL8 IL1A IL1B
36 11.81 CXCL8 IL1A IL1B TNF
37 11.76 IL1B TGFB1 TNF
38
Show member pathways
11.71 CXCL8 IL1A IL1B TNF
39 11.7 CCL2 CXCL8 EDN1 IL1A IL1B TGFB1
40 11.61 CXCL8 IL1B TNF
41 11.55 CCL2 IL1B TNF
42 11.54 EGFR IL1B TGFB1 TNF
43 11.54 CCL2 CXCL8 IL1B TGFB1 TNF
44 11.52 IL1A IL1B TNF
45
Show member pathways
11.47 ABCA3 SFTPB SFTPC SFTPD
46 11.45 CCL5 ITGA3 MUC1
47 11.45 CCL2 CCL5 CXCL8 IL1A IL1B TGFB1
48 11.42 CCL2 CCL5 CXCL8 IL1A IL1B TNF
49 11.39 IL1A IL1B TNF
50 11.39 CCL5 IL1A IL1B

GO Terms for Interstitial Lung Disease

Cellular components related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
2 extracellular space GO:0005615 9.55 ABCA3 CCL17 CCL2 CCL5 CXCL8 EDN1
3 endocytic vesicle GO:0030139 9.54 EGFR SFTPD TF
4 clathrin-coated endocytic vesicle GO:0045334 9.43 SFTPB SFTPC SFTPD
5 multivesicular body lumen GO:0097486 9.4 SFTPB SFTPC
6 lamellar body GO:0042599 9.33 SFTPB SFTPC SFTPD
7 alveolar lamellar body GO:0097208 9.32 ABCA3 SFTPB

Biological processes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 EGFR IL1B TGFB1 TNF
2 cellular protein metabolic process GO:0044267 9.99 ABCA3 SFTPB SFTPC SFTPD TF
3 MAPK cascade GO:0000165 9.99 CCL2 CCL5 EGFR IL1B TGFB1 TNF
4 chemotaxis GO:0006935 9.98 CCL17 CCL2 CCL5 CXCL8
5 positive regulation of cell migration GO:0030335 9.97 CCL5 EDN1 EGFR IL1B TGFB1
6 animal organ morphogenesis GO:0009887 9.93 CCL2 NKX2-1 SFTPB TNF
7 inflammatory response GO:0006954 9.92 CCL17 CCL2 CCL5 CXCL8 IL1A IL1B
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 CCL17 CCL2 CCL5 EGFR TGFB1 TNF
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 EGFR TGFB1 TNF
10 cellular response to interferon-gamma GO:0071346 9.9 CCL17 CCL2 CCL5 EDN1
11 cellular response to mechanical stimulus GO:0071260 9.89 EGFR IL1B TGFB1
12 regulation of insulin secretion GO:0050796 9.89 CCL5 IL1B TNF
13 cellular response to tumor necrosis factor GO:0071356 9.89 CCL17 CCL2 CCL5 CXCL8 EDN1
14 cellular response to drug GO:0035690 9.88 EDN1 EGFR IL1B
15 positive regulation of epithelial cell proliferation GO:0050679 9.88 CCL5 EGFR TGFB1
16 chemokine-mediated signaling pathway GO:0070098 9.87 CCL17 CCL2 CCL5 CXCL8
17 positive regulation of interleukin-6 production GO:0032755 9.86 IL1A IL1B TNF
18 positive regulation of MAP kinase activity GO:0043406 9.86 EDN1 EGFR TGFB1 TNF
19 positive regulation of cell division GO:0051781 9.85 IL1A IL1B TGFB1
20 monocyte chemotaxis GO:0002548 9.84 CCL17 CCL2 CCL5
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 CCL5 EDN1 EGFR TNF
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 IL1A IL1B TNF
23 negative regulation of mitotic cell cycle GO:0045930 9.81 EGFR TGFB1 TNF
24 cellular response to fibroblast growth factor stimulus GO:0044344 9.81 CCL2 CCL5 CXCL8
25 positive regulation of phagocytosis GO:0050766 9.8 IL1B SFTPD TNF
26 cellular response to organic cyclic compound GO:0071407 9.8 CCL2 CCL5 IL1B TGFB1 TNF
27 positive regulation of vascular endothelial growth factor production GO:0010575 9.79 IL1A IL1B TGFB1
28 positive regulation of mitotic nuclear division GO:0045840 9.79 EDN1 IL1A IL1B
29 negative regulation of myoblast differentiation GO:0045662 9.78 CCL17 TGFB1 TNF
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 EDN1 EGFR IL1B TNF
31 cellular response to interleukin-1 GO:0071347 9.77 CCL17 CCL2 CCL5 CXCL8 EDN1
32 respiratory gaseous exchange GO:0007585 9.76 EDN1 SFTPB SFTPC SFTPD
33 cerebral cortex cell migration GO:0021795 9.73 EGFR NKX2-1
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL1B TNF
35 PERK-mediated unfolded protein response GO:0036499 9.73 CCL2 CXCL8
36 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.73 IL1A IL1B
37 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.72 CCL5 CXCL8
38 neutrophil activation GO:0042119 9.72 CCL5 CXCL8
39 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.72 IL1A IL1B
40 macrophage chemotaxis GO:0048246 9.72 CCL2 CCL5 SFTPD
41 salivary gland morphogenesis GO:0007435 9.71 EGFR TGFB1
42 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 EGFR TGFB1
43 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
44 positive regulation of prostaglandin secretion GO:0032308 9.7 EDN1 IL1B
45 regulation of establishment of endothelial barrier GO:1903140 9.69 IL1B TNF
46 ectopic germ cell programmed cell death GO:0035234 9.69 IL1A IL1B
47 response to salt GO:1902074 9.68 EDN1 TGFB1
48 fever generation GO:0001660 9.67 IL1A IL1B
49 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
50 positive regulation of odontogenesis GO:0042482 9.66 EDN1 TGFB1

Molecular functions related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 CCL5 EGFR IFIH1 SFTPC SFTPD TGFB1
2 cytokine activity GO:0005125 9.28 CCL17 CCL2 CCL5 CXCL8 EDN1 IL1A
3 chemokine activity GO:0008009 9.26 CCL17 CCL2 CCL5 CXCL8
4 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5
5 protein binding GO:0005515 10.25 CCL2 CCL5 CXCL8 EDN1 EGFR IFIH1

Sources for Interstitial Lung Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....